(±)-CPSI-1306 is an orally available antagonist of macrophage migration inhibitory factor (MIF).

Product information

CAS Number: 1309793-47-2

Molecular Weight: 310.30

Formula: C15H16F2N2O3

Chemical Name: 2-[3-(2,4-difluorophenyl)-4,5-dihydro-1,2-oxazol-5-yl]-1-(morpholin-4-yl)ethan-1-one

Smiles: O=C(CC1CC(=NO1)C1=CC=C(F)C=C1F)N1CCOCC1

InChiKey: GUWOSEVHCSNYFK-UHFFFAOYSA-N

InChi: InChI=1S/C15H16F2N2O3/c16-10-1-2-12(13(17)7-10)14-8-11(22-18-14)9-15(20)19-3-5-21-6-4-19/h1-2,7,11H,3-6,8-9H2

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 6 mg/mL (19.34 mM; Need ultrasonic).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vivo:

Mice treated with CPSI-1306 show a significant drop in their blood glucose levels, which is associated with a reduction in serum levels of inflammatory cytokines. As expected, control mice treated with vehicle develop NIDDM as characterized by high serum levels of glucose and inflammatory cytokine. Furthermore, they also show that orally bioavailable CPSI-1306 can be effective in treating this disease. CPSI-1306-induced keratinocyte apoptosis could be appreciated as early as 30 minutes after a single UVB exposure. At 6, 24, and 48 hours following UVB exposure, the CPSI-1306-treated mice show significantly increased expression of cleaved caspase-3 compared with the vehicle-treated mice. CPSI-1306 reduces acute UVB-induced keratinocyte DNA damage and UVB-induced acute inflammation.

Products are for research use only. Not for human use.